A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects W/ Essential Thromboythemia Who Are Resistant to or Intolerant of
Clinical Trial Grant
Administered By
Medicine, Hematology
Awarded By
Incyte Corporation
Start Date
June 15, 2017
End Date
March 18, 2020
Administered By
Medicine, Hematology
Awarded By
Incyte Corporation
Start Date
June 15, 2017
End Date
March 18, 2020